A breakthrough in colorectal cancer research has emerged from South Korea, offering a potential new avenue for treatment as the disease sees alarming increases in younger adults. The findings, published January 14, 2026, in Nucleic Acids Research, detail how blocking a specific protein can slow the spread of the cancer.
The research centers on N-methyl-D-aspartate receptor synaptonuclear signaling and neuronal migration factor (NSMF), identified as a “novel and critical regulator of replication stress in colorectal cancer.” Scientists discovered that inhibiting NSMF induces “irreversible cellular aging” in tumor cells, effectively halting their rapid division and reducing DNA damage that fuels further mutations. Laboratory and animal experiments demonstrated that suppressing the NSMF gene slowed tumor growth and, in some instances, stopped it entirely.
According to the study, NSMF suppression prolonged survival in 33.5% of mouse models compared to untreated controls. Importantly, the blocking of NSMF did not harm healthy intestinal cells, a significant advantage over traditional chemotherapy which often impacts non-cancerous tissues.
Dr. Kyeong Jin Shin, lead author of the study and a researcher at Ulsan National Institute of Science and Technology, stated that developing medications to block the NSMF protein could represent a “novel treatment approach” for humans.
The urgency of this research is underscored by a concerning trend: rising colorectal cancer rates among younger adults. Dr. Céline Gounder, speaking on CBS News, noted that colorectal cancer is now the leading cause of cancer-related deaths for individuals under 50 in the United States. It remains the third-leading cause of cancer-related fatalities in men and the fourth in women, with an expected 55,230 deaths in 2026, according to the American Cancer Society.
While increased screening has lowered diagnosis rates in older adults, younger individuals have not experienced the same benefit. From 2013 to 2022, rates increased by 2.9% annually in those under 50, compared to a 0.4% increase in adults aged 50-64. Late diagnosis, often linked to lifestyle factors, diet, diabetes, tobacco and alcohol consumption, and family history, remains a primary driver of mortality, Dr. Gounder explained.
The recent deaths of actor James Van Der Beek, who passed away February 11, 2026, at age 48 after being diagnosed with the disease in 2023, and actress Catherine O’Hara, whose death was attributed to a pulmonary embolism caused by rectal cancer, have brought increased attention to the disease. Medical examiner reports revealed rectal cancer as the underlying cause of O’Hara’s death. Van Der Beek had previously shared that he initially dismissed early symptoms, attributing them to increased coffee intake and a sedentary lifestyle.
Following the actors’ passing, usage of the Colorectal Cancer Alliance’s free screening tool has reportedly tripled, and social media platforms have seen a surge in concern and discussion regarding prevention and early detection. One social media user commented on the potential environmental factors, stating, “The s**t in the food, sprayed in the air, unfiltered from our water… It’s amazing that anyone lives well into their 70s & 80s anymore.” Others are advocating for earlier screening ages, with some suggesting 42 instead of the recently recommended 45 by the US Preventive Services Task Force.
One individual shared a personal experience, stating, “IF YOU HAVE A HISTORY, GET SCREENED. My husband was 6 years away from the recommended age of screening, BUT because of a random symptom, he had a colonoscopy, and they found a pre-cancerous polyp. If we had waited, we would have been too late.”